Imagion Biosystems Limited
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more
Imagion Biosystems Limited (IBXXF) - Total Liabilities
Latest total liabilities as of June 2025: $4.80 Million USD
Based on the latest financial reports, Imagion Biosystems Limited (IBXXF) has total liabilities worth $4.80 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Imagion Biosystems Limited - Total Liabilities Trend (2014–2024)
This chart illustrates how Imagion Biosystems Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Imagion Biosystems Limited Competitors by Total Liabilities
The table below lists competitors of Imagion Biosystems Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ELECTRONIC ARTS - Dusseldorf Stock Exchang
DU:ERT
|
Germany | €5.73 Billion |
|
Tasman Resources Ltd
PINK:TASEF
|
USA | $19.89 Million |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
India | ₹258.93 Million |
|
PNC FINL SER
BE:PNP
|
Germany | €509.15 Billion |
|
VERISK ANLYTCS-A
BE:VA7A
|
Germany | €4.26 Billion |
|
Taoping Inc
NASDAQ:TAOP
|
USA | $15.84 Million |
|
M&T BANK - Dusseldorf Stock Exchang
DU:MTZ
|
Germany | €182.91 Billion |
|
Citra Nusa Holdings Bhd
KLSE:5104
|
Malaysia | RM13.49 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Imagion Biosystems Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imagion Biosystems Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imagion Biosystems Limited (2014–2024)
The table below shows the annual total liabilities of Imagion Biosystems Limited from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.09 Million | -39.26% |
| 2023-12-31 | $8.37 Million | +58.06% |
| 2022-12-31 | $5.30 Million | +554.19% |
| 2021-12-31 | $809.88K | -32.80% |
| 2020-12-31 | $1.21 Million | -36.52% |
| 2019-12-31 | $1.90 Million | +44.02% |
| 2018-12-31 | $1.32 Million | +91.39% |
| 2017-12-31 | $688.77K | +52.39% |
| 2016-12-31 | $451.99K | -95.32% |
| 2015-12-31 | $9.65 Million | +123.93% |
| 2014-12-31 | $4.31 Million | -- |